Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Open Access
- 21 March 2025
- journal article
- review article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-21
Abstract
Immunotherapy, particularly immune checkpoint inhibitor therapy, has demonstrated clinical benefits in solid tumours. Despite its satisfactory clinical efficacy, it still faces several issues, such as limited eligibility, low response rates and cytotoxicity. Cancer epigenetics implies that tumour cells exhibit unique phenotypes because of their unique characteristics, thus reprogramming of the epigenome holds promise for cancer therapy. Epigenetic regulation plays an important role in regulating gene expression during tumour development and maintenance. Epigenetic regulators induce cancer cell cycle arrest, apoptosis and differentiation of cancer cells, thereby exerting anti-tumour effects. Recent studies have revealed a significant correlation between epigenetic regulatory factors and immune checkpoint therapy. Epigenetics can modulate various aspects of the tumour immune microenvironment and immune response to enhance the sensitivity of immunotherapy, such as lowering the concentration required and mitigating cytotoxicity. This review primarily discusses DNA methyltransferase inhibitors, histone deacetylase inhibitors, enhancer of zeste homolog 2 inhibitors and lysine-specific demethylase 1 inhibitors, which are associated with transcriptional repression. This repression alters the expression of genes involved in the immune checkpoint, thereby enhancing the effectiveness of immunotherapy. We also discuss the potential and challenges of tumour immunotherapy and highlight its advantages, application challenges and clinical research on integrating epigenetic regulatory factors with tumour immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (32200462)
- Beijing Hospitals Authority Youth Programme (QML20231602)
- Beijing Municipal Administration of Hospitals Incubating Program (PX2021063)
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes (YY2023-14)
This publication has 199 references indexed in Scilit:
- Isolation and Single-Cell Transcriptomic Analysis of Murine Regulatory B Cells2024
- Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomesCancer Medicine, 2022
- Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesCancer, 2022
- Structural Biology of the Tumor Microenvironment2021
- Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation programCancer Immunology, Immunotherapy, 2021
- Immune modulation underpins the anti‐cancer activity of HDAC inhibitorsMolecular Oncology, 2021
- Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma ProgressionHepatology, 2021
- Tumor‐derived exosomes in the PD‐1/PD‐L1 axis: Significant regulators as well as promising clinical targetsJournal of Cellular Physiology, 2020
- JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expressionCell Biology International, 2019
- A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its InhibitorsMedicinal Research Reviews, 2015